Pentoxifylline Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
ConditionPsoriasis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorWasuchon Chaichan
About this trial
This study will evaluate whether pentoxifylline, when used as an add-on treatment to standard topical therapy, is effective and safe for adults with mild-to-moderate plaque psoriasis. Participants will be randomly assigned to receive either pentoxifylline or placebo twice daily for 12 weeks, while continuing their standard topical treatment. The study will compare improvement in psoriasis severity, itch, physician assessment, quality of life, and adverse events between the two groups. Participants will be followed for a total of 16 weeks.
Eligibility criteria
Qualifiers
Adults aged 18 to 65 years.
Clinical diagnosis of mild-to-moderate plaque psoriasis, defined as Psoriasis Area and Severity Index (PASI) score 3 to 10 or body surface area (BSA) involvement 3% to 10%, as assessed by a physician.
Receiving stable standard topical therapy for at least 2 weeks before enrollment.
Able and willing to provide written informed consent.
Disqualifiers
Use of biologic agents within 12 weeks before enrollment.
Psoriatic arthritis requiring systemic therapy.
Pregnant or breastfeeding.
Severe liver disease or severe kidney disease.
Trial design
Treatments tested in this trial
- Pentoxifylline 400 mg Oral Tablet
- Placebo
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wasuchon Chaichan
Lead sponsor
University of Phayao
Sponsor institution
Source ClinicalTrials.gov